Möchten Sie immer auf dem neuesten Stand bleiben?

NEW YORK, Feb. 23, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition...

NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, will...

NEW YORK, Jan. 19, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) announced today its key corporate goals and objectives for 2016, which include the following:   Aggressively...

NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, will...

ORLANDO, Fla, Dec. 07, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the presentation of pre-clinical data describing the synergy of the Company’s next generation...

Single agent TGR-1202 continues to demonstrate a favorable safety profile, differentiated from other PI3K delta inhibitors, with only 7% of patients discontinuing due to an adverse eventCollectively,...

Combination of TG-1101 plus TGR-1202 (“TG-1303”) continues to demonstrate a favorable safety profile, with only 8% of patients discontinuing due to an adverse event and no cases of colitis reported...

ORLANDO, Fla., Dec. 04, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today recapped the schedule of data presentations for their lead compounds at the upcoming 57th American...

NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its financial results for the third quarter ended September 30, 2015 and recent company...

Company to Host Third Quarter Earnings Conference Call to Review Financial Results, Business Updates as well as Provide an Overview of the ASH Abstract Data, on Monday November 9, 2015 at 8:30 am ET...